Resource Library

Discover Kymera’s research and resources on our exciting platform, pipeline, and additional cutting-edge technologies.

  • Programs & Targets

  • Indications

  • Year

  • Resource Type/Format

  • Development Stage

Related Resources

February 16, 2021

Targeted Protein Degradation in Oncology and Beyond

2nd Annual North American Protein Degradation Congress
Read More
February 16, 2021

Discovery of Potent and Selective STAT3 Targeted Protein Degraders with Excellent in vitro and in vivo ADME Properties

Oxford Global’s Virtual Symposium: Targeted Protein Degradation & PROTAC
Liquid Tumors Solid Tumors
Read More
December 7, 2020

Mechanisms of Anti-Tumor Activity of STAT3 Degraders in Lymphoma

62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition
Liquid Tumors
Read More
December 7, 2020

Targeting MYD88-Mutant DLBCL with IRAKIMiDs: A Comparison to IRAK4 Kinase Inhibition and Evaluation of Synergy with Rational Combinations

62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition
MYD88 Tumors
Read More
December 7, 2020

KTX-120, A Novel IRAKIMiD Degrader of IRAK4 and IMiD Substrates, Shows Preferential Activity and Induces Regressions in MYD88-Mutant DLBCL Cell and Patient Derived Xenograft Models

62nd American Society of Hematology (ASH) Virtual Annual Meeting and Exposition
MYD88 Tumors
Read More
October 15, 2020

Targeted Protein Degradation Beyond Oncology

3rd Annual Targeted Protein Degradation (TPD) Summit, Dr. Mainolfi
Read More
June 22, 2020

IRAKIMiDs: Protein degraders targeting both IRAK4 and IMiD substrates show combinatorial effects leading to broad activity with durable regressions in MYD88 mutant lymphoma xenografts in vivo

American Association for Cancer Research (AACR) Virtual Annual Meeting II
MYD88 Tumors
Read More
June 22, 2020

A STAT3-selective targeted protein degrader decreases the immune-suppressive tumor microenvironment and drives anti-tumor activity in preclinical models

American Association for Cancer Research (AACR) Virtual Annual Meeting II
Liquid Tumors Solid Tumors
Read More
December 7, 2019

Small molecule-induced, selective STAT3 degradation leads to anti-tumor activity in STAT3-dependent heme malignancies

American Society of Hematology (ASH) Annual Meeting
Liquid Tumors
Read More
October 26, 2019

Discovery of KYM-003, a potent and selective STAT3 degrader with anti-tumor activity in heme malignancies 

AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
Liquid Tumors
Read More